In a phase 2b trial of 257 patients with idiopathic pulmonary fibrosis, FVC fell 48.42 mL with combined deupirfenidone arms vs 110.71 mL with placebo over 26 weeks (Bayesian difference 62.29 mL; posterior probability 0.985). GI adverse events were most common.
RCTn = 257
Maher et al. Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial